Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2015) B. Eichhorst et al.   ANNALS OF ONCOLOGY

Apoptosis inducers in chronic lymphocytic leukemia

(2015) Christian Billard   Oncotarget

A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum

(2014) Haidar Akl et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia

(2014) Aksana Kaefer et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL, in patients with cancer

(2014) J. Yang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets

(2013) Meike Vogler et al.   BRITISH JOURNAL OF HAEMATOLOGY

Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition

(2013) Matthew S. Davids et al.   LEUKEMIA & LYMPHOMA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug–Drug Interaction Trial Design

(2010) M L Reitman et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

(2008) HX Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The BCL-2 protein family: opposing activities that mediate cell death

(2007) Richard J. Youle et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY